|
|
 Previous Article | Table of Contents | Next Article 
p53 overexpression as a marker of poor prognosis in mantle cell lymphomas
with t(11;14)(q13;q32)
DC Louie, K Offit, R Jaslow, NZ Parsa, VV Murty, A Schluger and RS Chaganti
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York,
NY 10021, USA.
The t(11;14)(q13;q32) translocation, which juxtaposes the BCL1 oncogene
with the Ig heavy chain locus, has been associated with an uncommon subtype
of non-Hodgkin's lymphoma (NHL) termed mantle cell lymphoma (MCL). To date,
no molecular marker that serves as an indicator of tumor progression or
clinical prognosis has been described for NHLs with this translocation. We
examined a panel of NHLs with t(11;14) for overexpression of p53 and
correlated the results with single-strand conformation polymorphism (SSCP)
analysis, karyotypic features, and clinical course. NHLs with t(11;14) were
identified from 30 patients. The diagnosis was MCL for 23 of 30, small
lymphocytic lymphoma for 4 of 30, and diffuse large-cell lymphoma for 3 of
30 cases. The results of immunohistochemistry analysis using a monoclonal
anti-p53 antibody on paraffin-embedded specimens were compared with the
SSCP data, the tumor karyotypes, and clinical course of each patient. DNA
sequencing of exons was performed on cases that showed conformational
changes by SSCP analysis. NHLs from 5 of 23 patients with MCL were positive
for p53 overexpression. Deletions of chromosome 17p were identified in 2 of
30 cases, both of which were MCLs showing p53 overexpression. Two of the
five MCLs with p53 overexpression showed evidence for TP53 mutations. None
of the 18 MCLs negative for p53 overexpression showed conformational
changes by SSCP. For these 18 patients with MCLs that did not overexpress
p53, the median survival was 63 months, compared with 12 months for the 5
patients with MCLs positive for p53 overexpression (P < .001). These
results suggest that p53 overexpression in MCL with t(11;14)(q13;q32) may
serve as a marker of poor prognosis.
Volume 86,
Issue 8,
pp. 2892-2899,
10/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Tabe, D. Sebasigari, L. Jin, M. Rudelius, T. Davies-Hill, K. Miyake, T. Miida, S. Pittaluga, and M. Raffeld
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Clin. Cancer Res.,
February 1, 2009;
15(3):
933 - 942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hartmann, V. Fernandez, V. Moreno, J. Valls, L. Hernandez, F. Bosch, P. Abrisqueta, W. Klapper, M. Dreyling, E. Hoster, et al.
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
J. Clin. Oncol.,
October 20, 2008;
26(30):
4966 - 4972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sander, L. Bullinger, E. Leupolt, A. Benner, D. Kienle, T. Katzenberger, J. Kalla, G. Ott, H. K. Muller-Hermelink, T. F.E. Barth, et al.
Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations
Haematologica,
May 1, 2008;
93(5):
680 - 687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kienle, T. Katzenberger, G. Ott, D. Saupe, A. Benner, H. Kohlhammer, T. F.E. Barth, S. Holler, J. Kalla, A. Rosenwald, et al.
Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors
J. Clin. Oncol.,
July 1, 2007;
25(19):
2770 - 2777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rudelius, S. Pittaluga, S. Nishizuka, T. H.-T. Pham, F. Fend, E. S. Jaffe, L. Quintanilla-Martinez, and M. Raffeld
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Blood,
September 1, 2006;
108(5):
1668 - 1676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fernandez, E. Hartmann, G. Ott, E. Campo, and A. Rosenwald
Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways
J. Clin. Oncol.,
September 10, 2005;
23(26):
6364 - 6369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bennaceur-Griscelli, J. Bosq, S. Koscielny, F. Lefrere, A. Turhan, N. Brousse, O. Hermine, and V. Ribrag
High Level of Glutathione-S-Transferase {pi} Expression in Mantle Cell Lymphomas
Clin. Cancer Res.,
May 1, 2004;
10(9):
3029 - 3034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, T. P. Miller, and O. A. O'Connor
Diffuse Aggressive Lymphoma
Hematology,
January 1, 2004;
2004(1):
221 - 236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kienle, A. Krober, T. Katzenberger, G. Ott, E. Leupolt, T. F. E. Barth, P. Moller, A. Benner, A. Habermann, H. K. Muller-Hermelink, et al.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome
Blood,
October 15, 2003;
102(8):
3003 - 3009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chiarle, L. M. Budel, J. Skolnik, G. Frizzera, M. Chilosi, A. Corato, G. Pizzolo, J. Magidson, A. Montagnoli, M. Pagano, et al.
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
Blood,
January 15, 2000;
95(2):
619 - 626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cuneo, R. Bigoni, G. M. Rigolin, M. G. Roberti, A. Bardi, N. Piva, R. Milani, F. Bullrich, M. L. Veronese, C. Croce, et al.
Cytogenetic Profile of Lymphoma of Follicle Mantle Lineage: Correlation With Clinicobiologic Features
Blood,
February 15, 1999;
93(4):
1372 - 1380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Cordone, S. Masi, F. R. Mauro, S. Soddu, O. Morsilli, T. Valentini, M. L. Vegna, C. Guglielmi, F. Mancini, S. Giuliacci, et al.
p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis
Blood,
June 1, 1998;
91(11):
4342 - 4349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R.K. Koduru, K. Raju, V. Vadmal, G. Menezes, S. Shah, M. Susin, J. Kolitz, and J. D. Broome
Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma
Blood,
November 15, 1997;
90(10):
4078 - 4091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Morente, M. A. Piris, V. Abraira, A. Acevedo, B. Aguilera, C. Bellas, M. Fraga, R. Garcia-Del-Moral, F. Gomez-Marcos, J. Menarguez, et al.
Adverse Clinical Outcome in Hodgkin's Disease Is Associated With Loss of Retinoblastoma Protein Expression, High Ki67 Proliferation Index, and Absence of Epstein-Barr Virus-Latent Membrane Protein 1 Expression
Blood,
September 15, 1997;
90(6):
2429 - 2436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Lens, P. J.J.C. De Schouwer, R. A. Hamoudi, M. Abdul-Rauf, N. Farahat, E. Matutes, T. Crook, M. J.S. Dyer, and D. Catovsky
p53 Abnormalities in B-Cell Prolymphocytic Leukemia
Blood,
March 15, 1997;
89(6):
2015 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Wilson, J. Teruya-Feldstein, T. Fest, C. Harris, S. M. Steinberg, E. S. Jaffe, and M. Raffeld
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas
Blood,
January 15, 1997;
89(2):
601 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pinyol, L. Hernandez, M. Cazorla, M. Balbin, P. Jares, P. L. Fernandez, E. Montserrat, A. Cardesa, C. Lopez-Otin, and E. Campo
Deletions and Loss of Expression of P16INK4a and P21Waf1 Genes Are Associated With Aggressive Variants of Mantle Cell Lymphomas
Blood,
January 1, 1997;
89(1):
272 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
